证券代码：300453 证券简称：三鑫医疗 公告编号：2026-010 江西三鑫医疗科技股份有限公司 关于董事会换届选举的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 江西三鑫医疗科技股份有限公司（以下简称"公司"或"本公司"）第五届董 事会任期即将届满。为顺利完成公司董事会的换届选举工作，根据《中华人民共和 国公司法》（以下简称《公司法》）《上市公司独立董事管理办法》《深圳证券交 易所上市公司自律监管指引第 2 号--创业板上市公司规范运作》等法律法规、规范 性文件及《公司章程》的相关规定，现将公司第六届董事会的组成、选举方式、董 事候选人的提名推荐、本次换届选举的程序以及董事候选人任职资格等事项公告如 下： 一、第六届董事会的组成 公司第六届董事会由 9 名董事组成，其中非独立董事 6 名（包含 1 名职工代表 董事），独立董事 3 名。董事（不含职工代表董事）由股东会选举或更换，任期自 公司相关股东会选举通过之日起计算，每届任期三年。职工代表董事由公司职工通 过职工代表大会、职工大会或者其他形式民主选举产生，任期与第六届董事会任期 保持一致。 公 ...

本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 江西三鑫医疗科技股份有限公司（以下简称"公司"）于近日收到德国莱茵 TÜV 集团换发的欧盟医疗器械法规 Medical Devices Regulation（EU）2017/745 （以下简称"MDR"）认证证书，现将主要情况公告如下： 一、获得 MDR 认证的产品情况 公司本次获得欧盟 MDR 认证的三项产品分别为透析液过滤器（Dialysis Fluid Filters）、连续性血液净化管路及附件（CRRT Tubing Sets）、预充式 导管冲洗器（Pre-Filled Flush Syringes）。 公司产品一次性使用血液透析管路（Hemodialysis Blood Tubing Sets）、 一次性使用机用采血器（A.V. Fistula Needle Sets）、一次性使用无菌注射针 （Sterile Hypodermic Needles）、一次性使用回缩自毁式无菌注射器 带针 （Sterile Retractable Safety Syringes for Single Use）、一次性使用精密 过 ...

Group 1 - Ninebot Company achieved a revenue of 21.325 billion yuan in 2025, a year-on-year increase of 50.22%, and a net profit of 1.755 billion yuan, up 61.84% [1] - Huizhong Co., Ltd. reported a revenue of 450 million yuan in 2025, a 16.79% increase, with a net profit of 66.2099 million yuan, up 14.7% [2] - Dalian Heavy Industry achieved a revenue of 15.501 billion yuan in 2025, an 8.54% increase, with a net profit of 588 million yuan, up 18.17% [3] - Jiepte's optical connection business is still in its early stages, contributing less than 5% to total revenue, with uncertainties due to market demand and competition [4] - Yuanguang Software reported a revenue of 2.593 billion yuan in 2025, an 8.12% increase, with a net profit of 301 million yuan, up 2.8% [5] - Kaipu Cloud reported a revenue of 418 million yuan in 2025, a 32.24% decrease, with a net loss of 10.8071 million yuan [6] - Cambricon achieved a total revenue of 6.497 billion yuan in 2025, a 453.21% increase, with a net profit of 2.059 billion yuan, compared to a loss of 452 million yuan in the previous year [7] - Sanxin Medical reported a revenue of 1.64 billion yuan in 2025, a 9.31% increase, with a net profit of 262 million yuan, up 15.43% [8] - Wanji Technology won a project bid worth 22 million yuan, aligning with its smart connected business development plan [9] - Xingrong Environment proposed a cash dividend of approximately 2.35 yuan per 10 shares for 2025, based on a 35% payout ratio of net profit [10] - Lankai Technology achieved a revenue of 5.456 billion yuan in 2025, a 49.94% increase, with a net profit of 2.236 billion yuan, up 58.35% [11] - Muxi Co., Ltd. reported a revenue of 1.644 billion yuan in 2025, a 121.26% increase, but incurred a net loss of 778 million yuan [12] - Hubei Yihua reported a revenue of 25.659 billion yuan in 2025, a 1.04% increase, with a net profit of 889 million yuan, down 16.74% [13] - Microchip Bio proposed a share buyback plan of 80 million to 120 million yuan for employee stock ownership [14] - Moore Thread reported a revenue of 1.506 billion yuan in 2025, a 243.37% increase, with a net loss of 1.024 billion yuan [15] - Huace Navigation achieved a revenue of 3.681 billion yuan in 2025, a 13.24% increase, with a net profit of 681 million yuan, up 16.7% [16] - Jiangfeng Electronics reported a revenue of 4.605 billion yuan in 2025, a 27.75% increase, with a net profit of 481 million yuan, up 20.15% [17] - Wol Nuclear Materials achieved a revenue of 8.451 billion yuan in 2025, a 22% increase, with a net profit of 1.135 billion yuan, up 33.95% [18] - Shenghong Co., Ltd. reported a revenue of 3.463 billion yuan in 2025, a 14.07% increase, with a net profit of 474 million yuan, up 10.58% [19] - Sun Paper achieved a revenue of 39.184 billion yuan in 2025, a 3.79% decrease, with a net profit of 3.258 billion yuan, up 5.05% [20] Group 2 - Wuhan Tianyuan's actual controller plans to reduce holdings by up to 1.93% of the company's shares [21][22] - Zhenghai Bio's shareholder plans to reduce holdings by up to 2% of the company's shares [23] - Baiwei Storage reported a revenue of 11.296 billion yuan in 2025, a 68.72% increase, with a net profit of 867 million yuan, up 437.56% [24] - Jierong Technology received a notice of investigation from the China Securities Regulatory Commission for suspected information disclosure violations [25] - Tengda Construction won a bid for a city parking lot construction project worth 172 million yuan [26] - Jiazhen New Energy's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Jiabiou reported a revenue of 575 million yuan in 2025, a 3.47% increase, with a net profit of 157 million yuan, up 26.15% [28] - Jingsheng Co., Ltd.'s shareholder plans to reduce holdings by up to 3% of the company's shares [29] - Chengdi Xiangjiang's subsidiary signed a significant contract with Shanghai Unicom, with an estimated contract value of 642 million yuan [30] - Guoci Materials plans to acquire 100% of Australian-listed company SDI for 166 million AUD (approximately 816 million yuan) [31] - Zhongfutong plans to raise no more than 643 million yuan through a private placement for various projects [32] - Yuanjie Technology reported a revenue of 601 million yuan in 2025, a 138.5% increase, with a net profit of 191 million yuan, compared to a loss of 6.134 million yuan in the previous year [33] - *ST Dazheng's shareholder plans to reduce holdings by up to 1% of the company's shares [34] - Huasheng Tiancheng clarified its cooperation model with Huawei, indicating that it has a minor impact on overall revenue [35] - Fenghuo Communication reported that its low-orbit satellite communication business contributes less than 1% to total revenue [36] - Huasheng Chang plans to acquire 100% of Jialante's shares for 460 million yuan [37] - Hekang New Energy plans to raise no more than 1.652 billion yuan from Midea Group for various projects [38] - Shuangliang Energy is under investigation by the CSRC for misleading information disclosure [39] - Jingfang Technology reported a revenue of 1.474 billion yuan in 2025, a 30.44% increase, with a net profit of 370 million yuan, up 46.23% [40][41] - Zhongji Xuchuang reported a revenue of 38.24 billion yuan in 2025, a 60.25% increase, with a net profit of 10.799 billion yuan, up 108.81% [42] - Shunluo Electronics reported a revenue of 6.745 billion yuan in 2025, a 14.39% increase, with a net profit of 1.021 billion yuan, up 22.71% [43] - Visual China plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [44] - Haitai Development is under investigation by the CSRC for information disclosure violations [45] - Biyin Lefen's controlling shareholder plans to increase holdings by 100 million to 200 million yuan [46] - Tapa Group reported a revenue of 4.107 billion yuan in 2025, a 3.99% decrease, with a net profit of 634 million yuan, up 17.87% [47] - Lite Optoelectronics plans to invest in a quartz fabric R&D center and production base with a total investment of 1 billion yuan [48] - Demingli reported a revenue of 10.789 billion yuan in 2025, a 126.07% increase, with a net profit of 688 million yuan, up 96.35% [49] - Shengke Communication's state-owned investment fund reduced its shareholding to 13% [50] - Tongxing Technology plans to invest in a sodium-ion battery anode material project with a total investment of approximately 500 million yuan [51] - *ST Rindong applied to revoke the delisting risk warning for its stock, reporting a net profit of 360 million yuan in 2025, compared to a loss of 833 million yuan in the previous year [53] - Guoli Electronics reported a revenue of 1.323 billion yuan in 2025, a 66.98% increase, with a net profit of 70.6089 million yuan, up 133.51% [54] - Jingzhida plans to raise no more than 2.959 billion yuan through a private placement for various projects [55] - Hongdian Film reported a revenue of 2.298 billion yuan in 2025, a 16.55% increase, with a net profit of 159 million yuan, compared to a loss of 96.376 million yuan in the previous year [56] - Jingzhida's shareholders plan to reduce holdings by up to 1.55% of the company's shares [57] - Xin Anjie announced that its chairman is under investigation and has been detained [58]

Core Viewpoint - The blood dialysis machine market in China is experiencing rapid growth, with the market size expected to reach 4.131 billion yuan by 2025, reflecting a year-on-year increase of 6.4% [1][6]. Industry Overview - Blood dialysis machines, also known as artificial kidneys, are essential medical devices for treating renal failure and uremia, consisting of a blood monitoring alarm system and a dialysis liquid supply system [3][4]. - The increasing elderly population and rising prevalence of chronic kidney diseases are driving the demand for blood dialysis machines [5][6]. Market Size and Growth - The market size for blood dialysis machines in China is projected to grow significantly, driven by an aging population and an increasing number of patients requiring dialysis treatment [1][6]. - The number of patients undergoing dialysis in China is expected to rise from 385,100 in 2015 to 1,027,300 by 2024, with male patients making up a significant portion of this demographic [5][6]. Competitive Landscape - The Chinese blood dialysis machine industry is primarily dominated by foreign companies such as Fresenius Medical, B. Braun, Baxter, and Nipro, indicating substantial room for domestic companies to capture market share [7][8]. - Domestic companies are enhancing their R&D capabilities, leading to improvements in technology and product quality, which positions them to compete more effectively against international brands [7][8]. Industry Development Trends - The process of domestic substitution for blood dialysis machines is accelerating, with local companies focusing on core technology and key component development to reduce reliance on foreign brands [10][11]. - Future technological advancements in blood dialysis machines will focus on smart and precise upgrades, integrating IoT and AI for improved monitoring and safety [11][12]. - The application scenarios for blood dialysis machines are expanding beyond traditional hospitals to include community healthcare settings and home dialysis solutions, driven by the increasing demand for accessible and convenient treatment options [12].

Group 1 - The company, Sanxin Medical, announced a total operating revenue of 1,640.09 million yuan for the year 2025, representing a year-on-year growth of 9.31% [2] - The net profit attributable to shareholders of the listed company reached 262.49 million yuan, showing a year-on-year increase of 15.43% [2]

Major Announcements - Cambrian reported a net profit of 2.059 billion yuan for 2025, turning around from a loss of 450 million yuan in the previous year, with total revenue reaching 6.497 billion yuan, a year-on-year increase of 453.21% [12] - Moer Thread achieved total revenue of 1.506 billion yuan in 2025, marking a year-on-year growth of 243.37%, although it still reported a net loss of 1.024 billion yuan [13] - Zhongji Xuchuang's net profit for 2025 grew by 108.81% year-on-year, reaching 10.799 billion yuan, with total revenue of 38.24 billion yuan, up 60.25% [14] Company Performance Reports - Xirong Environment proposed a cash dividend of approximately 2.35 yuan per 10 shares for 2025, based on a payout ratio of 35% of the net profit attributable to shareholders [2] - Jietu's optical connection business is still in its early stages, contributing less than 5% to total revenue, with growth dependent on various market factors [3] - Zhongying Technology plans to acquire at least 51% of Yingzhong Electric, which specializes in insulation fiber materials [4] - Xibu Superconductor's subsidiary, Juneng Magnet, will be listed on the National Equities Exchange and Quotations starting March 2, 2026 [5] - Ingrity Media announced that some of its bank accounts have had their funds unfrozen, allowing normal operations to resume [6][7] - Dayun Technology plans to establish a joint venture to enhance its semiconductor testing capabilities, with a registered capital of 11 million yuan [7] Financial Highlights - Huazhong Technology reported a net profit of 1.36 billion yuan for 2025, a decrease of 31.19%, despite total revenue increasing by 55.85% to 18.616 billion yuan [36] - Jiangfeng Electronics achieved a net profit of 481 million yuan, up 20.15%, with total revenue of 4.605 billion yuan, a 27.75% increase [20] - Ninebot Company reported a net profit of 1.755 billion yuan, a year-on-year increase of 61.84%, with total revenue of 21.325 billion yuan, up 50.22% [24] - Weicai Technology's net profit reached 300 million yuan, a 134% increase, with total revenue of 1.575 billion yuan, up 46.22% [25] - Dalian Heavy Industry reported a net profit of 588 million yuan, an 18.17% increase, with total revenue of 15.501 billion yuan, up 8.54% [26]

Core Viewpoint - Sanxin Medical (300453.SZ) reported a revenue of 1.64 billion yuan for the fiscal year 2025, reflecting a year-on-year growth of 9.31%, and a net profit attributable to shareholders of 260 million yuan, which is a 15.43% increase compared to the previous year [1] Group 1: Financial Performance - The company achieved total operating revenue of 1.64 billion yuan, marking a 9.31% increase from the same period last year [1] - The net profit attributable to shareholders reached 260 million yuan, representing a year-on-year growth of 15.43% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses also showed steady growth, indicating enhanced profitability [1] Group 2: Strategic Initiatives - The company focused on strategic development goals and operational plans, executing work in an orderly manner [1] - It made precise judgments on market demand, continuously promoting product iteration and innovation [1] - The company strengthened its international market layout and expanded market share while implementing cost reduction and efficiency enhancement measures [1] Group 3: Competitive Positioning - The company has enhanced its main business competitiveness, laying a solid foundation for long-term value enhancement [1] - The ongoing efforts in refining operational levels have contributed to the improvement of profitability [1]

Core Viewpoint - Sanxin Medical (300453.SZ) reported a net profit of 260 million yuan for 2025, reflecting a year-on-year growth of 15.43% [1] Financial Performance - The company achieved total operating revenue of 1.64 billion yuan, an increase of 9.31% compared to the previous year [1] - The net profit attributable to shareholders of the listed company reached 260 million yuan, marking a 15.43% increase year-on-year [1] - The net profit attributable to shareholders, after deducting non-recurring gains and losses, also showed steady growth [1] Strategic Initiatives - The company focused on strategic development goals and operational plans, effectively executing its work during the reporting period [1] - It emphasized precise market demand judgment, continuous product iteration and innovation, and strengthened international market layout [1] - The company implemented cost reduction and efficiency enhancement measures, improving operational precision and reinforcing profitability [1]

Core Viewpoint - Sanxin Medical announced a total operating revenue of 1.64 billion yuan for the fiscal year 2025, representing a year-on-year growth of 9.31% [1] Financial Performance - The net profit attributable to shareholders of the listed company reached 262 million yuan, an increase of 15.43% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 239 million yuan, reflecting a year-on-year growth of 14.01% [1] Asset and Equity Growth - As of the end of the reporting period, total assets amounted to 2.427 billion yuan, which is a 9.19% increase compared to the beginning of the period [1] - The equity attributable to shareholders of the listed company was 1.456 billion yuan, showing a growth of 9.95% from the start of the period [1] - The net asset per share stood at 2.79 yuan, marking a 10.28% increase from the beginning of the period [1] Reporting Status - The performance report is unaudited, with specific data to be disclosed in the annual report [1]

Group 1 - The core viewpoint of the article highlights the financial performance of Sanxin Medical for the fiscal year 2025, showing a positive growth trend in both revenue and net profit [1] - The company's operating revenue is approximately 1.64 billion yuan, representing a year-on-year increase of 9.31% [1] - The net profit attributable to shareholders of the listed company is about 262 million yuan, reflecting a year-on-year increase of 15.43% [1] - The basic earnings per share is 0.5076 yuan, which is a year-on-year increase of 14.95% [1]